Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Media Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Third Quarter 2024 Financial Results Collaboration revenue increased by $1.2 million to $3.3 million for the three months ended September 30, 2024, from $2.1 million for the three months ended ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

First Immutep reported on positive data from the Phase I trial evaluating its eftilagimod alpha (efti) in combination with ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...